Ignite Creation Date:
2025-12-25 @ 2:19 AM
Ignite Modification Date:
2026-05-20 @ 1:06 AM
Study NCT ID:
NCT01460134
Status:
COMPLETED
Last Update Posted:
2018-01-31
First Post:
2011-10-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Sponsor:
Celldex Therapeutics
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma | View |
| None | Chronic Lymphocytic Leukemia | View |
| None | Mantle Cell Lymphoma | View |
| None | Marginal Zone B Cell Lymphoma) | View |
| None | Any T-cell Malignancy | View |
| None | Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma | View |
| None | Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer | View |
| None | Colorectal Adenocarcinoma, Non-small Cell Lung Cancer) | View |
| None | Burkett's Lymphoma | View |
| None | Primary Lymphoma of the Central Nervous System | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | CD27 expressing Hematologic Malignancies | View |
| None | CD27 expressing Solid Tumors | View |
| None | chronic lymphocytic leukemia | View |
| None | Burkett's lymphoma | View |
| None | mantle cell lymphoma | View |
| None | primary lymphoma of the central nervous system | View |
| None | marginal zone B cell lymphoma | View |
| None | solid tumor | View |
| None | metastatic melanoma | View |
| None | renal (clear) cell carcinoma | View |
| None | hormone-refractory prostate adenocarcinoma | View |
| None | ovarian cancer | View |
| None | colorectal adenocarcinoma | View |
| None | non-small cell lung cancer | View |